Odd Coupling: J&J, RallyBio Collaborate As Only Firms Focused On FNAIT

While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.